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Introduction
Solid tumors trigger intrinsic inflammatory responses that promote tumorigenesis and metastasis (1) (2) . CD11b+ myeloid cells, which include granulocytes, macrophages, and myeloid derived suppressors cells progressively accumulate in primary tumor sites, where they promote tumor angiogenesis, invasion and progression (3) (4) (5) . Several studies have shown correlations between tumor-associated macrophage (TAM) abundance and unfavorable tumor outcomes (6-7).
TAMs secrete pro-angiogenic cytokines and growth factors, including VEGF-A, TNFĮ, IL-6, IL-8 and bFGF (3) (4) 8) , as well as MMP-9, which can promote angiogenesis by releasing pro-angiogenic factors such as VEGF-A from the extracellular matrix (9) (10) (11) . These cells also express IL-10 and TGF-β, which suppress anti-tumor immune responses (12) (13) (14) (15) . A number of tumor-derived chemoattractants, including stromal derived growth factor 1 alpha (SDF-1Į), colony-derived stimulating factor (CSF-1) interleukin-1 beta (IL-1β), and monocyte chemoattractant protein-1 (MCP-1), can recruit angiogenesis-promoting myeloid cells into tumors and stimulate tumor invasiveness (5, 8, 12, 16) . As tumor inflammation develops in most growing tumors and in response to chemotherapeutic interventions, leading to relapses in tumor growth (9, 17) , agents that block tumor inflammation promise to be useful therapeutics for solid tumors.
We recently found that integrin α4β1 on the surface of immune cells promotes endothelial progenitor and myeloid cell recruitment to tumors (18) (19) . Antagonists of integrin α4β1 disrupt the interaction between α4β1 and its ligand VCAM-1, thereby inhibiting immune cell adhesion to the endothelium (18) (19) (20) . Chemokine-induced signaling promotes increased integrin affinity and avidity, and clustering of integrins at 4 the cytoplasmic membrane, leading to leukocyte arrest on inflamed endothelium (20) (21) . In this study, we identify new roles for tumor-derived inflammatory factors in the activation of myeloid cell integrin α4β1 during myeloid cell recruitment to the tumor microenvironment. Combinatorial administration of antagonists of integrin α4 and tumorderived chemoattractants or chemotherapeutic agents potently suppressed tumor inflammation and growth in tumor models. 
Materials and Methods: Animals
PyMT+ mice (22) and integrin α4Y991A mice (23) were derived as described.
C57BL/6 mice were obtained from Charles River and C57BL/6-Tg(ACTB-EGFP) mice were from Jackson Laboratories.
Isolation and quantification of myeloid cells from tissues by flow cytometry
To quantify myeloid cells, tissues were excised, minced and digested for 1h at 37°C in 10ml of Hanks Balanced Salt Solution (HBSS, GIBCO) containing 1 mg/ml Collagenase type IV (Sigma), 10 mg/ml Hyaluronidase type V (Sigma) and 20 units/ml DNase type IV (Sigma). Cells were incubated in FC-blocking reagent (BD Bioscience), followed by CD11b-APC (M1/70, eBioscience) and Gr1-FITC (RB6-8C5, eBioscience).
To exclude dead cells, 2.5μg/ml propidium iodide (PI) was added before data acquisition by FACs Calibur (BD Bioscience). Myeloid cells from human buffy coats, murine BM, or enzymatically digested tumor tissue were purified by anti-CD11b magnetic bead affinity chromatography (Miltenyi Biotec).
Gene and protein expression
Total RNA was isolated from tissue or cells using ISOGEN (Nippon Gene). qPCR was performed using primers for SDF-1α, IL-1β, TNF-α, IL-8 and IL-6 from Qiagen Transcript levels were normalized to GAPDH. SDF-1Į and IL-1ȕ protein levels were determined in lysates of cultured cells, whole tumors or from tumor derived CD11b+/-cells using Quantikine mouse SDF-1Į and IL-1ȕ kits (R&D Systems).
Cell biological and biochemical assays
Adhesion and integrin activation assays were previously described (24) . For immunoprecipitations, BM monocytic cells from WT or α4Y991A mice were treated with basal or conditioned medium for 30min at 37ºC. Cells were lysed in Tris-buffered saline containing 1%CHAPS, 20 mM ȕ-glycerophosphate, 1mM Na 3 VO 4 , 5mM NaF, 100ng/ml microcystin-LR, and protease inhibitor cocktail. Cell lysates were immunoprecipitated with 5ȝg of rat anti-α4β1 (PS/2) antibody overnight, followed by addition of 25ȝl of protein G-conjugated Dynabeads for 3h with rotation. Protein precipitates were electrophoresed and immunoblotted with anti-integrin Į4 (C-20, Santa Cruz Biotechnology), anti-paxillin (H-114, Santa Cruz Biotechnology), or anti-talin (Clone TD77, Chemicon) antibodies. Immune complexes were visualized using an enhanced chemiluminescence detection kit (Pierce). 
In vivo assays

Results
IL-1β and SDF-1α recruit pro-angiogenic monocytic cells to the tumor microenvironment
To determine whether specific inflammatory factors recruit myeloid cells to Both SDF-1α and IL-1β can promote hematopoietic cell trafficking and tumor inflammation (25) (26) . To compare the roles of IL-1β and SDF-1α in myeloid cell recruitment to tumors and subsequent angiogenesis, we transplanted ACTB-EGFP bone marrow into wildtype mice and, 4 weeks later, implanted growth factor-depleted Matrigel containing saline, IL-1β or SDF-1α into mice. We then evaluated the number of GFP+ bone marrow derived cells and blood vessels in Matrigel plugs ( Figure 1H ). SDF-1α and IL-1β both stimulated recruitment of GFP+ bone marrow derived cells as well as new blood vessel growth (Fig. 1H ). These findings indicate that both SDF-1α and IL-1β directly recruit bone marrow derived cells and stimulate angiogenesis. As tumor cells express SDF-1α, and myeloid cells express IL-1β, these studies suggest that both tumor and myeloid cells promote tumor inflammation.
Blockade of IL-1β or SDF-1α inhibits tumor inflammation and growth.
To determine whether SDF-1α and IL-1β recruit myeloid cells during LLC tumor progression, mice bearing LLC tumors were treated for 10 days with antagonists of SDF-1α or IL-1β; tumor inflammation and growth was analyzed. Anti-IL1β significantly suppressed tumor growth ( Fig. 2A) as well as myeloid cell recruitment and angiogenesis (Fig. 2B) . These results suggest that inhibition of myeloid cell recruitment by IL-1β
antagonists decreased tumor blood vessel formation. Similarly, blockade of SDF-1α signaling with the CXCR4 antagonist AMD3100 inhibited LLC tumor growth (Fig. 2C) myeloid cell recruitment and angiogenesis (Fig. 2D) . Both inhibitors reduced expression levels of SDF-1α, IL-1β, IL-6, TNFα and VEGF-A in tumors (Fig. 2E) , of IL-1β, IL-6 and VEGF-A in tumor-derived macrophages (Fig. 2F) and of IL-1β in tumor-derived CD11b+Gr1hi granulocytes ( Supplementary Fig. 4 ). Taken together, these findings indicate that IL-1β and SDF-1α recruit tumor-promoting myeloid cells to the tumor microenvironment and that inhibition of these inflammatory factors blocks myeloid cell recruitment to tumors, thereby inhibiting angiogenesis and resulting in suppressed tumor growth.
Inflammatory factors induce integrin α4β1 activation and clustering
Immune cell extravasation depends upon activation of integrins by chemoattractant-stimulated adhesion of cells to vascular endothelium. We investigated whether specific tumor-derived inflammatory factors promote integrin-dependent myeloid cell adhesion to the endothelium. Fluorescently labeled murine myeloid cells exhibited increased adhesion to vascular endothelium after a brief (30 minute) stimulation by purified SDF-1α, IL-1β, or LLC tumor cell-conditioned medium (TCM, which contains largely SDF-1α, TNF-α and VEGF-A), (Fig. 3A) . This adhesion event was mediated by integrin α4, as antagonists of integrin α4 and siRNA-mediated knockdown of integrin α4 expression blocked myeloid cell adhesion to endothelium, while antagonists of other myeloid cell integrins, including αvѽ α5, and αM, had no effects (Fig. 3A, Supplementary Fig. 5A-B) .
We therefore investigated the role of receptor-mediated signaling in integrin α4- 
TLR/IL-1β receptor signaling, failed to adhere to the endothelium in the presence of IL-1β ҏ but adhered normally in the presence of SDF-1α (Fig. 3B) , indicating that IL-1R-mediated signal transduction is required for IL-1β-induced adhesion. Similarly, pertussis toxin and AMD3100 inhibited SDF-1α-induced, but not IL-1β induced adhesion, indicating that CXCR4-mediated signal transduction is necessary for SDF-1α and TCMinduced cell adhesion to the endothelium (Fig. 3B) , indicating that SDF-1α is a key active component in TCM (Fig. 3B) . Together, these data indicate that diverse tumorderived chemoattractants promote integrin α4β1-mediated myeloid cell adhesion using non-overlapping signaling pathways.
Chemokine signaling can promote rapid conformational changes in integrin β chains that rapidly unfold integrin heterodimers and increase their affinity for ligand (20) (21) (27) (28) . These changes can be detected by the binding of a monoclonal antibody, HUTS21, to newly revealed epitopes on the human β1 ҏ integrin subunit (21) . To determine whether tumor derived factors induce conformational changes in integrins of myeloid cells, we stimulated human myeloid cells for 10 minutes with 200 ng/ml SDF-1α, IL-1β, or Mn2+ (a positive control) and performed flow cytometry to detect binding of HUTS21 and P4C10, an antibody that recognizes β1 integrins regardless of conformation. SDF-1α and IL-1β increased HUTS21 binding but had no effect on P4C10 binding, indicating that SDF-1α and IL-1β can activate myeloid cell β1 integrins without affecting integrin expression (Fig. 3C ).
Conformational changes in integrins can alter their avidity for ligand by inducing integrin clustering within the plane of the lipid bilayer. Therefore, we examined the effect 
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of SDF-1α and IL-1β on integrin α4β1 clustering. Both SDF-1α and IL-1β rapidly (within 5 minutes) stimulated integrin α4 clustering in human and murine myeloid cells (Fig. 3D,   Supplementary Fig. 6 ). Receptor-mediated signaling is required for IL-1β and SDF-1α-induced integrin α4 clustering, as IL-1β-stimulated MyD88-/-cells and SDF-1α-stimulated wildtype cells treated with PTX or AMD3100 exhibited no integrin α4 clustering (Fig. 3E) . These studies support the hypothesis that tumor-derived factors stimulate integrin α4β1-mediated myeloid cell adhesion by increasing both the affinity and the avidity of integrin α4β1.
Inflammatory factors regulate integrin α4 activation by increasing integrin α4 interactions with paxillin and talin
Activation of integrin α4β1 depends on association of talin with an NPXY domain inҏ β1 cytoplasmic tails, and its adhesion under flow depends on association of paxillin with tyrosine991 within the integrin α4 cytoplasmic tail (20, 23, (27) (28) (29) . We therefore evaluated integrin α4β1 co-clustering with paxillin and talin in myeloid cells from WT mice and from mice expressing an α4 Y991A mutation (α4Y991A), which disrupts the α4 integrin-paxillin binding site and partially disrupts α4β1 interactions with talin (23). IL-1β and SDF-1α rapidly (within 5 minutes) stimulated integrin α4 clustering in WT but not α4Y991A cells (Fig. 4A) . Inflammatory mediators induced co-clustering of integrin α4β1 with paxillin and talin in WT but not α4Y991A myeloid cells (Fig. 4B-C Supplementary Fig. 7 ). In addition, paxillin and talin co-immunoprecipitated with integrin α4β1 in myeloid cells from WT but not α4Y991A mice upon stimulation with TCM (Fig. 4D) . Importantly, α4Y991A myeloid cells failed to adhere in response to SDF-1α or IL-1β (Fig. 4E ) and exhibited defective cell migration on the α4 integrin ligand VCAM-1 but not on vitronectin, an αv integrin ligand (Fig. 4F) .
Combination of integrin α4 antagonists with inflammatory inhibitors effectively block tumor inflammation and growth
As SDF-1α and IL-1β can stimulate integrin α4β1-mediated adhesion to endothelium in vitro, we asked whether these factors stimulate integrin α4β1 mediated trafficking of myeloid cells into tumors in vivo. Fluorescently labeled myeloid cells injected intravenously into mice rapidly accumulated in established tumors ( Figure 5A ).
In contrast, myeloid cells that were co-injected with antagonists of SDF-1α, IL-1β or integrin α4β1 failed to accumulate in tumors (Fig. 5A) . Notably, combined blockade of SDF-1α and IL1β reduced the recruitment of myeloid cells to tumors to the same extent as integrin α4β1 blockade, supporting the idea that activation of integrin α4β1 by both SDF-1α and IL-1β plays a critical role in tumor inflammation. Importantly, trafficking of myeloid cells to other organs was not affected (Fig. 5A ). Our results demonstrate that tumor-derived SDF-1α and macrophage-derived IL-1β activate integrin α4 and together promote myeloid cell recruitment to the tumor microenvironment. To determine whether antagonists of integrin α4, IL-1β and SDF-1α in combination could have beneficial anti-tumor effects, we evaluated the effects of treating LLC tumors with the integrin α4 function-blocking antibody PS2, the SDF-1α inhibitor AMD3100 and anti-IL-1β antibodies alone or in combination. Treatment with AMD3100, anti-IL1β, or anti-α4 alone inhibited tumor growth, reducing tumor burdens to approximately 50% that of untreated tumors (Fig. 5B) . Combined administration of anti-IL-1β and AMD3100 further suppressed tumor growth, while combined blockade of integrin α4 and SDF-1α or IL1β reduced tumor growth by 80% (Fig. 5B) . Combination therapies also strongly blocked tumor inflammation (Fig. 5C ). These findings indicate that targeting inflammation by blocking integrin α4 and inflammatory factors such as IL-1β or SDF-1α may provide therapeutic benefit in the treatment of solid tumors.
Targeting integrin α4 reduces tumor inflammation and growth in spontaneous tumor models
To determine whether small molecule integrin antagonists could block tumor inflammation and growth, we evaluated the effect of the small molecule inhibitor of integrin α4, ELN476063, on myeloid cell adhesion in vitro and on tumor inflammation in vivo. ELN476063 efficiently blocked IL-1β, SDF-1α and TCM stimulated myeloid cell adhesion to the integrin α4 ligand VCAM-1 (Fig. 6A ) and reduced LLC primary tumor growth (Fig. 6B) . ELN476063 significantly inhibited myeloid cell infiltration of LLC tumors and tumor angiogenesis (Fig. 6C) . We also evaluated the effects of α4 antagonists on spontaneous breast tumor growth by treating PyMT+ FVB mice with the ELN476063 integrin α4 antagonist (from postnatal 6w-9w). Treated mice exhibited reduced tumor burden, reduced macrophage content, and decreased blood vessel density (Fig. 6D) . In support of these findings are our findings that spontaneous PyMT/α4Y991A breast tumors exhibited reduced tumor inflammation, growth and progression (24) . Altogether, our data indicate that blockade of integrin α4 inhibits the recruitment of pro-angiogenic myeloid cells to the tumor microenvironment, therefore impairing tumor progression.
Blockade of integrin α4 in combination with chemotherapeutic agents
Radiation and chemotherapy can induce inflammatory responses that complicate cancer therapy (30) (31) (32) . Blockade of inflammation may improve responsiveness or prevent resistance to therapeutic agents. Microtubule-inhibiting vascular disrupting agents (VDAs) damage the tumor endothelium, resulting in decreased tumor vascularization and reduced tumor growth over the long term. However, these drugs rapidly induce extensive tumor inflammation (Fig. 7A-C) . To determine whether inhibition of myeloid cell recruitment can suppress inflammation associated with cancer therapeutics, pre-established LLC tumors were treated with VDA OXi4503 in the presence and absence of an integrin α4 antagonist. OXi4503 inhibited short-term tumor growth (Fig. 7A ), but stimulated inflammation (Fig. 7B-C) and new blood vessel formation in tumors (Fig. 7C) α4β1 antagonists, tumor inflammation, angiogenesis and growth were strongly inhibited, and tumor necrosis was enhanced (Fig. 7D) .
To determine whether longer term combinations of chemotherapeutic agents and integrin α4 inhibitors could synergize to reduce tumor growth and metastasis, we treated Lewis lung carcinomas and orthotopic murine Panc02 pancreatic carcinomas with gemcitabine, anti-integrin α4 or both together for three weeks. Combination of gemcitabine and anti-α4β1 antibodies suppressed tumor growth, inflammation, angiogenesis and metastasis to a much greater extent than either agent alone ( CAN-11-0588 20 to the endothelium. As blockade of receptor signaling abolished inside-out activation of integrin α4β1, our findings indicate that myeloid cell trafficking is tightly controlled by receptor mediated signal transduction.
Discussion
Integrin α4β1 activation is regulated by binding of the α4 integrin cytoplasmic tail to the adaptor protein paxillin, which stabilizes integrin α4β1-ligand binding (27) (28) .
Here, we observed that paxillin-integrin α4 interactions are required for integrin clustering and for myeloid cell adhesion to the endothelium. Similarly, the adaptor molecule talin also interacts with integrin α4β1 upon stimulation. Binding of talin to the integrin β1 chain promotes conformational changes of integrin α4β1 to its active state.
Our data provide evidence that blockade of α4β1 with these adapter proteins affects the biological function of primary myeloid cells. 
